Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adial Pharmaceuticals (ADIL) Other financing activities (2022 - 2024)

Adial Pharmaceuticals' Other financing activities history spans 3 years, with the latest figure at $51878.0 for Q3 2024.

  • For Q3 2024, Other financing activities changed N/A year-over-year to $51878.0; the TTM value through Sep 2024 reached $808570.0, changed N/A, while the annual FY2023 figure was $749943.0, 91.78% down from the prior year.
  • Other financing activities for Q3 2024 was $51878.0 at Adial Pharmaceuticals, up from $48987.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $7.5 million in Q4 2022 and bottomed at $48987.0 in Q1 2024.
  • The 3-year median for Other financing activities is $437655.0 (2022), against an average of $1.2 million.
  • The largest annual shift saw Other financing activities dropped 29.93% in 2023 before it tumbled 87.67% in 2024.
  • A 3-year view of Other financing activities shows it stood at $7.5 million in 2022, then crashed by 95.84% to $310263.0 in 2023, then plummeted by 83.28% to $51878.0 in 2024.
  • Per Business Quant, the three most recent readings for ADIL's Other financing activities are $51878.0 (Q3 2024), $48987.0 (Q1 2024), and $310263.0 (Q2 2023).